Literature DB >> 6863910

A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity.

A Clark, C W Potter, R Jennings, J P Nicholl, A F Langrick, G C Schild, J M Wood, D A Tyrrell.   

Abstract

Groups of volunteers were immunized with one of three influenza virus vaccines, and the resistance to challenge infection with attenuated influenza A (H1N1) virus was measured 8 months later. The vaccines were aqueous subunit influenza A/USSR/77 (H1N1) vaccine, aqueous subunit influenza B/Hong Kong/73 vaccine, or attenuated influenza virus A (H1N1) vaccine. The B virus vaccine was included as a control to assess the incidence of natural A virus infection during the study period. A proportion of the B virus vaccinees had pre-existing A (H1N1) virus antibody and were used to study the immunity conferred by natural infection to the live virus challenge. The serum antibody responses were measured at 1 and 8 months after immunization. The results showed that all the vaccines induced serum HI antibody in a proportion of the volunteers; however, after 1 month, higher titres of serum antibody were found in volunteers given inactivated A vaccine than in those given live attenuated A virus vaccine. Eight months post-immunization the titres of serum antibody in volunteers given inactivated vaccine had declined significantly, but there were no changes in the antibody titres of those given live virus vaccine. The incidence of infection by the challenge virus at 8 months post-immunization was directly related to the serum antibody titres 1 month post-immunization; no evidence was obtained to suggest that those given live virus vaccine had a more solid immunity than those given inactivated vaccine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6863910      PMCID: PMC2134281          DOI: 10.1017/s0022172400028990

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  12 in total

1.  Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic.

Authors:  G MEIKLEJOHN; C H KEMPE; W G THALMAN; E H LENNETTE
Journal:  Am J Hyg       Date:  1952-01

Review 2.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

3.  Influenza antibody in human respiratory secretions after subcutaneous or respiratory immunization with inactivated virus.

Authors:  J A Kasel; R V Fulk; Y Togo; R B Hornick; G G Heiner; A T Dawkins; J J Mann
Journal:  Nature       Date:  1968-05-11       Impact factor: 49.962

4.  Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine.

Authors:  J A Kasel; E B Hume; R V Fulk; Y Togo; M Huber; R B Hornick
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

5.  Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2 ) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines.

Authors:  D S Freestone; S Hamilton-Smith; G C Schild; R Buckland; S Chinn; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1972-09

6.  Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man.

Authors:  B R Murphy; E G Chalhub; S R Nusinoff; J Kasel; R M Chanock
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

7.  A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.

Authors:  A Clark; C W Potter; R Jennings; J P Nicholl; A F Langrick; G C Schild; J M Wood; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1983-06

8.  A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.

Authors:  M I Brady; I G Furminger
Journal:  J Hyg (Lond)       Date:  1976-10

9.  Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains.

Authors:  F van Voorthuizen; D Jens; F Saes
Journal:  Antiviral Res       Date:  1981-06       Impact factor: 5.970

10.  Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine.

Authors:  C W Potter; R Jennings; J P Phair; A Clarke; C H Stuart-Harris
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226

View more
  17 in total

1.  A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.

Authors:  Laurent Coudeville; Philippe Andre; Fabrice Bailleux; Françoise Weber; Stanley Plotkin
Journal:  Hum Vaccin       Date:  2010-10-01

2.  Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.

Authors:  Alina C Boesteanu; Nadarajan S Babu; Margaret Wheatley; Elisabeth S Papazoglou; Peter D Katsikis
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 4.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

5.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

Authors:  M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

6.  Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine.

Authors:  R Jennings; T L Smith; A R Mellersh; A Clark; R C Spencer; C W Potter
Journal:  J Hyg (Lond)       Date:  1985-02

7.  Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis.

Authors:  R Al-Khayatt; R Jennings; C W Potter
Journal:  J Hyg (Lond)       Date:  1984-10

8.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

9.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

Review 10.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.